Fortrea Holdings (FTRE) Current Deferred Revenue (2022 - 2026)

Fortrea Holdings (FTRE) posted Current Deferred Revenue of $481.3 million for Q1 2026, up 1.58% on a QoQ basis from $473.8 million in Q4 2025, and up 15943.33% year-over-year from N/an in Q1 2025.

Fortrea Holdings (FTRE) Current Deferred Revenue (2022 - 2026) Analysis & Trends

Fortrea Holdings' Current Deferred Revenue history runs 5 years deep, the most recent figure standing at $481.3 million for Q1 2026.

  • Quarterly Current Deferred Revenue rose 15943.33% year-over-year to $481.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $481.3 million (up 15943.33% YoY) and the FY2025 annual result came in at $473.8 million, up 34.11% from the prior year.
  • Current Deferred Revenue was $481.3 million for Q1 2026 at Fortrea Holdings, up from $473.8 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $481.3 million in Q1 2026 and bottomed at $3.0 million in Q1 2025.
  • A 5-year average of $302.0 million and a median of $271.5 million in 2022 frame the typical range for Current Deferred Revenue.
  • Annual changes were most pronounced in 2025 — Current Deferred Revenue sank 98.73% — and 2026, when it jumped 15943.33%.
  • Fortrea Holdings' Current Deferred Revenue stood at $271.5 million in 2022, then declined by 21.1% to $214.2 million in 2023, then jumped by 64.94% to $353.3 million in 2024, then jumped by 34.11% to $473.8 million in 2025, then grew by 1.58% to $481.3 million in 2026.
  • Business Quant data shows FTRE's Current Deferred Revenue at $481.3 million in Q1 2026, $473.8 million in Q4 2025, and $411.6 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 67,102.16 Bn 67,101.87 Bn -
2 Nanobiotix 1,908.96 Bn 1,908.90 Bn -
3 Akari Therapeutics 959.56 Bn 959.56 Bn -
4 BeOne Medicines 474.03 Bn 469.24 Bn 1.35 Bn
5 Vertex Pharmaceuticals 122.13 Bn 114.88 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 70.09 Bn 61.34 Bn 3.31 Bn
7 Belite Bio 62.34 Bn 62.34 Bn -
8 Argenx Se 55.96 Bn 50.77 Bn 1.41 Bn
9 Alnylam Pharmaceuticals 37.53 Bn 34.52 Bn 959.66 Mn
10 Fortrea Holdings 1.83 Bn 1.68 Bn 123.60 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 481.30 Mn
Dec 31, 2025 473.80 Mn
Sep 30, 2025 411.60 Mn
Jun 30, 2025 381.70 Mn
Mar 31, 2025 3.00 Mn
Dec 31, 2024 353.30 Mn
Sep 30, 2024 321.10 Mn
Jun 30, 2024 248.00 Mn
Mar 31, 2024 236.90 Mn
Dec 31, 2023 214.20 Mn
Sep 30, 2023 264.80 Mn
Jun 30, 2023 264.30 Mn
Dec 31, 2022 271.50 Mn